DeterioRAtion under the control of T cells: and MTX is not just an antimetabolite after all
Medicomunicare Magazine
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint deterioration. The clinical outcomes of patients with active RA can be improved using anti-rheumatic medications, such as methotrexate (MTX). Many patients rely on MTX to limit the destructive joint damage and functional disability typical of RA. Although the drug is a folic acid antagonist,